- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT00887822
A Study of Bevacizumab (Avastin) Versus Placebo in Combination With Capecitabine (Xeloda) and Cisplatin as First-Line Therapy for Advanced Gastric Cancer (AVATAR)
10. januar 2017 opdateret af: Hoffmann-La Roche
A Double-Blind, Randomized, Multicenter, Phase III Study of Bevacizumab in Combination With Capecitabine and Cisplatin Versus Placebo in Combination With Capecitabine and Cisplatin, as First-Line Therapy in Patients With Advanced Gastric Cancer.
This 2 arm study will compare the efficacy and safety of bevacizumab in combination with capecitabine and cisplatin versus placebo in combination with capecitabine and cisplatin in participants who have not received prior chemotherapy for advanced or metastatic gastric cancer.
Participants will be randomized to one of two treatment groups Bevacizumab + Capecitabine/Cisplatin (experimental arm) or Placebo + Capecitabine/Cisplatin (control arm).
Studieoversigt
Status
Afsluttet
Betingelser
Intervention / Behandling
Undersøgelsestype
Interventionel
Tilmelding (Faktiske)
202
Fase
- Fase 3
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiesteder
-
-
-
Beijing, Kina, 100021
-
Beijing, Kina, 100142
-
Beijing, Kina, 100071
-
Beijing, Kina, 100853
-
ChongQing, Kina, 400042
-
Guangzhou, Kina, 510060
-
Hangzhou, Kina, 310016
-
Nanjing, Kina
-
Nanjing, Kina, 210036
-
Shanghai, Kina, 200032
-
Shanghai, Kina, 200080
-
Shantou, Kina, 515041
-
Shenyang, Kina, 110001
-
Wuhan, Kina, 430030
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
18 år og ældre (Voksen, Ældre voksen)
Tager imod sunde frivillige
Ingen
Køn, der er berettiget til at studere
Alle
Beskrivelse
Inclusion Criteria:
- Histologically confirmed adenocarcinoma of the stomach or gastro-oesophageal junction with inoperable, locally advanced or metastatic disease, not amenable to curative therapy
- Eastern Cooperative Oncology Group (ECOG) performance status of 0,1 or 2
- Measurable disease or non-measurable but evaluable disease, according to the Response Evaluation Criteria in Solid Tumors (RECIST)
Exclusion Criteria:
- Previous chemotherapy for locally advanced or metastatic gastric cancer
- Previous platinum or anti-angiogenic therapy
- Radiotherapy within 28 days of randomization
- Evidence of Central Nervous System (CNS) metastasis at baseline
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Dobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Bevacizumab, Capecitabine and Cisplatin
Participants will receive bevacizumab 7.5 milligrams per kilogram (mg/kg) intravenous (IV) infusion on Day 1 of every 3-week cycle in combination with capecitabine 1000 milligrams per square meter (mg/m^2) orally twice daily (total daily dose 2000 mg/m^2) on Days 1-14 of every 3-week cycle and cisplatin 80 mg/m^2 IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles; until disease progression or unmanageable toxicity.
|
7.5 mg/kg IV infusion on Day 1 of every 3-week cycle
Andre navne:
1000 mg/m^2 orally twice daily on Days 1-14 of every 3-week cycle
Andre navne:
80 mg/m^2 IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles
|
|
Placebo komparator: Placebo, Capecitabine and Cisplatin
Participants will receive placebo matched to bevacizumab on Day 1 of every 3-week cycle in combination with capecitabine 1000 mg/m^2 orally twice daily (total daily dose 2000 mg/m^2) on Days 1-14 of every 3-week cycle and cisplatin 80 mg/m^2 IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles; until disease progression or unmanageable toxicity.
|
1000 mg/m^2 orally twice daily on Days 1-14 of every 3-week cycle
Andre navne:
80 mg/m^2 IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles
Placebo matched to bevacizumab on Day 1 of every 3-week cycle
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Percentage of Participants With Event (Death)
Tidsramme: From randomization until death (up to 34 months)
|
Percentage of participants who died due to any cause was reported.
As planned, ad hoc analysis was done for overall survival up to clinical cut-off date of 12 January 2012 (34 months), subsequent to the protocol-defined clinical cut-off date of 13 May 2011 (26 months).
Overall survival was defined as the time between randomization and the date of death due to any cause.
|
From randomization until death (up to 34 months)
|
|
Overall Survival
Tidsramme: From randomization until death (up to 34 months)
|
Overall survival was defined as the time between randomization and the date of death due to any cause.
Overall survival was estimated using Kaplan Meier method.
Reported data included censored observations.
Participants for whom no death was captured on the clinical database were censored at the most recent date they were known to be alive.
As planned, ad hoc analysis was done for overall survival up to clinical clinical cut-off date of 12 January 2012 (34 months), subsequent to the protocol-defined clinical cut-off date of 13 May 2011 (26 months).
|
From randomization until death (up to 34 months)
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Percentage of Participants With Progression-Free Survival (PFS) Events (Disease Progression/Death)
Tidsramme: From randomization until disease progression or death (up to 26 months)
|
Progression of disease was defined as at least 20 percent (%) increase in the sum of longest diameters of target lesions compared to the smallest sum of longest diameters on-study and absolute increase of at least 5 millimeters (mm), progression of existing non-target lesions, or presence of new lesions.
PFS was defined as the time between randomization and the date of first documented disease progression or death, whichever occurred first, according to Response Evaluation Criteria In Solid Tumors (RECIST).
|
From randomization until disease progression or death (up to 26 months)
|
|
Progression-Free Survival (PFS)
Tidsramme: From randomization until disease progression or death (up to 26 months)
|
PFS was defined as the time between randomization and the date of first documented disease progression or death, whichever occurred first, according to RECIST.
Progression of disease was defined as at least 20% increase in the sum of longest diameters of target lesions compared to the smallest sum of longest diameters on-study and absolute increase of at least 5 mm, progression of existing non-target lesions, or presence of new lesions.
PFS was estimated using Kaplan Meier method.
Reported data included censored observations.
Participants who had neither progressed nor died at the time of study completion or who were lost to follow-up were censored at the date of the last tumor assessment or last follow-up for progression of disease.
Participants for whom no post-baseline tumor assessments were available were censored at day of randomization.
|
From randomization until disease progression or death (up to 26 months)
|
|
Percentage of Participants With PFS Events (Disease Progression/Death) During First-line Therapy
Tidsramme: From randomization until disease progression or death (up to 26 months)
|
Progression of disease was defined as at least 20% increase in the sum of longest diameters of target lesions compared to the smallest sum of longest diameters on-study and absolute increase of at least 5 mm, progression of existing non-target lesions, or presence of new lesions.
PFS during first-line therapy was defined as the time between randomization and the date of first documented disease progression or death, whichever occurred first and only if it occurred no later than 28 days after last confirmed intake of any study medication and before the start of non-study antineoplastic treatment, according to RECIST.
|
From randomization until disease progression or death (up to 26 months)
|
|
PFS During First-line Therapy
Tidsramme: From randomization until disease progression or death (up to 26 months)
|
PFS during first-line therapy was defined as time between randomization and date of first documented disease progression or death, whichever occurred first and only if it occurred no later than 28 days after last intake of any study medication and only if it occurred before start of non-study antineoplastic treatment, according to RECIST.
Progression of disease was defined as at least 20% increase in sum of longest diameters of target lesions compared to smallest sum of longest diameters on-study & absolute increase of at least 5 mm, progression of existing non-target lesions, or presence of new lesions.
PFS was estimated using Kaplan Meier method.
Reported data included censored observations.
Participants who neither progressed nor died in this interval, or who were lost to follow-up were censored at date of last tumor assessment/last follow-up within this time window.
Participants for whom no post-baseline tumor assessments were available were censored at day of randomization.
|
From randomization until disease progression or death (up to 26 months)
|
|
Percentage of Participants With Disease Progression
Tidsramme: From randomization until disease progression or death (up to 26 months)
|
Progression of disease was defined as at least 20% increase in the sum of longest diameters of target lesions compared to the smallest sum of longest diameters on-study and absolute increase of at least 5 mm, progression of existing non-target lesions, or presence of new lesions.
|
From randomization until disease progression or death (up to 26 months)
|
|
Time to Progression
Tidsramme: From randomization until disease progression or death (up to 26 months)
|
Time to progression was defined as the time between randomization and the first occurrence of disease progression.
Progression of disease was defined as at least 20% increase in the sum of longest diameters of target lesions compared to the smallest sum of longest diameters on-study and absolute increase of at least 5 mm, progression of existing non-target lesions, or presence of new lesions.
Time to progression was estimated using Kaplan Meier method.
Reported data included censored observations.
Participants who had not progressed at the time of study completion (including participants who had died before disease progression) or who were lost to follow-up were censored at the date of the last tumor assessment or last follow-up for progression of disease.
Participants for whom no post-baseline tumor assessments were available were censored at day of randomization.
|
From randomization until disease progression or death (up to 26 months)
|
|
Percentage of Participants With Best Overall Response as Assessed by RECIST During First-Line Therapy
Tidsramme: From randomization until disease progression or death (up to 26 months)
|
Best overall response during first-line therapy was defined as the occurrence of either a confirmed complete (CR) or a partial response (PR), as assessed by the RECIST criteria.
CR: disappearance of all target and non-target lesions (TLs) and normalization of tumor markers.
Pathological lymph nodes must have short axis measures less than (<) 10 mm.
PR: at least a 30 % decrease in the sum of measures (longest diameter for tumor lesions and short axis measure for nodes) of TLs, taking as reference the baseline sum of longest diameters.
|
From randomization until disease progression or death (up to 26 months)
|
|
Duration of Response During First-Line Therapy
Tidsramme: From randomization until disease progression or death (up to 26 months)
|
Duration of response during first-line therapy was defined as the time from when response (CR or PR) was first documented to first documented disease progression or death (whichever occurs first) during first-line therapy.
CR: disappearance of all target and non-TLs and normalization of tumor markers.
Pathological lymph nodes must have short axis measures <10 mm.
PR: at least a 30 % decrease in the sum of measures (longest diameter for tumor lesions and short axis measure for nodes) of TLs, taking as reference the baseline sum of longest diameters.
Duration of response was estimated using Kaplan Meier method.
Reported data included censored observations.
Participants who did not progress or die after they had had a confirmed response were censored at the date of their last tumor measurement or last follow-up for progression of disease during first line therapy.
|
From randomization until disease progression or death (up to 26 months)
|
|
Percentage of Participants With Disease Control During First-Line Therapy
Tidsramme: From randomization until disease progression or death (up to 26 months)
|
Disease control was defined as stable disease(SD) for 6 weeks or longer, CR plus PR as assessed by RECIST criteria for participants with measurable disease.CR:disappearance of all TLs & normalization of tumor markers.
Pathological lymph nodes must have short axis measures<10 mm.
PR:at least 30% decrease in sum of measures(longest diameter for tumor lesions and short axis measure for nodes)of TLs, taking as reference baseline sum of longest diameters.SD:neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for disease progression taking as reference smallest sum of longest diameters on study.
For participants without measurable disease, clinical benefit rate was defined as no clinical disease progression for >/=6 weeks.
Disease progression was defined as at least 20% increase in sum of diameters of TLs compared to smallest sum of diameters on-study and absolute increase of at least 5 mm, progression of existing non-target lesions, or presence of new lesions.
|
From randomization until disease progression or death (up to 26 months)
|
|
Change From Cycle 1 in European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 36 (QLQ-C30) Scale Over Time
Tidsramme: From Cycle 1 until disease progression (up to 26 months)
|
EORTC QLQ-C30 included global health status (GHS)/quality of life (QOL), functional scales (physical, role, cognitive, emotional, and social), symptom scales (fatigue, pain, nausea/vomiting), and single items (dyspnea, appetite loss, insomnia, constipation, diarrhea, and financial difficulties).
Most questions used a 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used a 7-point scale (1 'Very Poor' to 7 'Excellent').
Scores were averaged and transformed to 0-100 scale; a higher score for Global Qol/functional scales=better level of QoL/functioning, or a higher score for symptom scale=greater degree of symptoms.
|
From Cycle 1 until disease progression (up to 26 months)
|
|
Change From Cycle 1 in EORTC QLQ-STO22 Scale Over Time
Tidsramme: From Cycle 1 until disease progression (up to 26 months)
|
The EORTC QLQ-STO22 is a gastric cancer quality of life questionnaire.
There are 22 questions which comprise 5 scales (dysphagia, pain, reflux symptom, dietary restrictions, and anxiety) and 4 single items (dry mouth, hair loss, taste, body image).
Most questions used 4-point scale (1 'Not at all' to 4 'Very much'; 1 question was a yes or no answer).
A linear transformation was used to standardize all scores and single-items to a scale of 0 to 100; higher score=better level of functioning or greater degree of symptoms.
|
From Cycle 1 until disease progression (up to 26 months)
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart
1. marts 2009
Primær færdiggørelse (Faktiske)
1. maj 2011
Studieafslutning (Faktiske)
1. august 2014
Datoer for studieregistrering
Først indsendt
22. april 2009
Først indsendt, der opfyldte QC-kriterier
23. april 2009
Først opslået (Skøn)
24. april 2009
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
1. marts 2017
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
10. januar 2017
Sidst verificeret
1. januar 2017
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Sygdomme i fordøjelsessystemet
- Neoplasmer
- Neoplasmer efter sted
- Gastrointestinale neoplasmer
- Neoplasmer i fordøjelsessystemet
- Gastrointestinale sygdomme
- Mavesygdomme
- Neoplasmer i maven
- Lægemidlers fysiologiske virkninger
- Molekylære mekanismer for farmakologisk virkning
- Antimetabolitter, Antineoplastisk
- Antimetabolitter
- Antineoplastiske midler
- Antineoplastiske midler, immunologiske
- Angiogenese-hæmmere
- Angiogenesemodulerende midler
- Vækststoffer
- Væksthæmmere
- Cisplatin
- Capecitabin
- Bevacizumab
Andre undersøgelses-id-numre
- ML22367
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .